NCT06861244 2026-04-13
PNOC031
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
15 trialsNCT07284589 2026-04-08
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT04412629 2026-04-06
Cabozantinib in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04067726 2026-03-31
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT07276360 2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2 Recruiting
NCT05692635 2026-03-20
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT07447076 2026-03-03
Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07284563 2025-12-16
Ultralow Dose PET Imaging for 18F-NaF Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT06086704 2025-10-01
Study of 18F-FFNP Breast PET/MRI
University of Wisconsin, Madison
Phase 2 Recruiting
NCT01920737 2025-09-16
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04017962 2025-08-11
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06620835 2025-07-29
OPTALK
Groupe Francais De Pneumo-Cancerologie
Phase 2 Recruiting
NCT06904313 2025-06-04
Ultralow Dose PET Imaging for PSMA Expression
Nuclear Imaging Institute
Phase 2 Recruiting
NCT06956391 2025-06-04
Ultralow Dose PET Imaging of 18F-FDG Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed